News | BTG Specialty Pharmaceuticals

Date

Title

01 Dec 2020

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business
12 Nov 2020

Initial study results show feasibility of outpatient methotrexate administration with planned-use Voraxaze® (glucarpidase) during COVID-19 pandemic

BTG Specialty Pharmaceuticals highlights study inspired by COVID-19 pandemic conditions, presented at Society for NeuroOncology annual conference
17 Aug 2020

European Medicines Agency has accepted for review a marketing authorisation application for Voraxaze
23 Apr 2020

Study Underway to Examine the Planned Use of Voraxaze® with Methotrexate in CNS Lymphoma

Initial study results shared on American Academy of Neurology website